Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Hyperlipidemia

Hyperlipidemia

Subtypes of Hyperlipidemia

Hypertriglyceridemia 7 Hypercholesterolemia 6 Familial hypercholesterolemia 2 Familial combined hyperlipidemia 1

31 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hyperlipidemia

89 trials tracked for Hyperlipidemia: 35 in phase 3 or 4 and 13 with published results. The most-cited published study has 511 citations.

89Trials tracked
35Phase 3 & 4
0Recruiting
13With published results
Phase distribution
Phase 4 11 Phase 3 24 Phase 2 15 Phase 1 5 Other / NA 34
  1. Phase 3 Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 Completed · 511 cited
  2. Phase 3 Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events Completed · 363 cited
  3. Phase 3 Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia Completed · 363 cited
  4. Phase 3 Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events Completed · 363 cited
  5. Phase 3 Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins Completed · 363 cited
  6. Phase 3 A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy Completed · 360 cited
Show 44 more trials
  1. Phase 4 Stop Atherosclerosis in Native Diabetics Study Completed · 247 cited
  2. Phase 4 Self-Assessment Method for Statin Side-effects Or Nocebo Completed · 180 cited
  3. Phase 4 Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling Completed · 97 cited
  4. Phase 3 Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events Completed · 60 cited
  5. Phase 3 Calorie Restriction and Changes in Body Composition, Disease, Function, and Quality of Life in Older Adults Completed · 38 cited
  6. Phase 3 Effect of Evolocumab on Coronary Atherosclerosis Completed · 14 cited
  7. Phase 4 Exploratory Study of the Effect of Omega-3-acid Ethyl Esters (TAK-085) on Vascular Endothelial Function in Patients With Hyperlipidemia by Flow Mediated Dilation Completed · 2 cited
  8. Phase 4 Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and Lipoprotein Profile in the Blood Completed
  9. Phase 4 Lipid Management in Renal Transplant Recipients Using Evolocumab. Completed
  10. Phase 4 Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients Completed
  11. Phase 4 Telephone Based Management of Hyperlipidemia Completed
  12. Phase 4 A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction Completed
  13. Phase 4 Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin Completed
  14. Phase 4 Effects of Omega-3 Fatty Acids on the Human Gene Expression Completed
  15. Phase 3 Sitagliptin Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans Completed
  16. Phase 3 A Human Trial to Evaluate the Efficacy and Safety of Aged Garlic Powder on Improvement of Blood Lipids in Subjects With Hyperlipidemia Completed
  17. Phase 3 Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2 Completed
  18. Phase 3 Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 Completed
  19. Phase 3 An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia Completed
  20. Phase 3 Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin Completed
  21. Phase 3 Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study Completed
  22. Phase 3 LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 Completed
  23. Phase 3 Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 Completed
  24. Phase 3 Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy Completed
  25. Phase 3 Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia Completed
  26. Phase 3 Effect of MK0524A on Cholesterol Levels (0524A-048) Completed
  27. Phase 3 Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress Completed
  28. Phase 3 Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia Completed
  29. Phase 3 An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME) Completed
  30. Phase 2 Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels Completed
  31. Phase 2 Phase II Study of Heart Polypill Safety and Efficacy in Primary Prevention of Cardiovascular Disease Completed
  32. Phase 2 Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects Completed
  33. Phase 2 Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS Completed
  34. Phase 2 Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects Completed
  35. Phase 2 Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration Completed
  36. Phase 2 Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease Completed
  37. Phase 2 Fish Oil and Alpha Lipoic Acid in Treating Alzheimer's Disease Completed
  38. Phase 2 Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia Completed
  39. Phase 2 The SCCS Polypill Pilot Trial Completed
  40. Phase 2 Compare the Efficacy and Safety of Beta-Glucan as Add-On to Statin in Subjects With Hyperlipidemia. Completed
  41. Phase 2 Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia Completed
  42. Phase 2 A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70) Completed
  43. Phase 2 LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy Completed
  44. Phase 2 The Effect of Farlong® NotoGinseng™ (Ginseng Plus®) on Cholesterol and Blood Pressure Completed

Showing the 50 most-cited and recently-updated of 89 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
APOA5 p.R223C variant linked to substantially higher fasting triglycerides in a Chinese family
Genetics & Precision Medicine Guideline
APOA5 p.R223C variant linked to substantially higher fasting triglycerides in a Chinese family Likely Pathogenic APOA5 Variant Linked to High Triglycerides in Chinese Family
This guideline presents a case report of a Chinese family with an APOA5 p.R223C variant. Fasting triglyceride levels were substantially high…
A case report suggests a specific APOA5 variant causes high triglycerides in some Chinese family members, though more research is needed.
Frontiers Jun 2, 2026
Cerivastatin best for total cholesterol, simvastatin for LDL-C in DKD with hyperlipidemia
Diabetes & Endocrinology Meta-analysis
Cerivastatin best for total cholesterol, simvastatin for LDL-C in DKD with hyperlipidemia Lipid-Lowering Drugs Show Different Benefits for Kidney Disease
A network meta-analysis of 20 RCTs in patients with diabetic kidney disease and hyperlipidemia found that cerivastatin most effectively redu…
A review of 20 trials found that different statins and fenofibrate have unique effects on cholesterol, kidney markers, and heart risks in di…
Frontiers May 29, 2026
Narrative review on PCSK9 inhibitors for familial hypercholesterolemia
Drug Pipeline Sys. Review
Narrative review on PCSK9 inhibitors for familial hypercholesterolemia Review explores PCSK9 inhibitors for familial hypercholesterolemia
This narrative review synthesizes evidence on PCSK9 inhibitors, including evolocumab, for familial hypercholesterolemia. The authors discuss…
This review looks at PCSK9 inhibitors like evolocumab for people with familial hypercholesterolemia. It discusses how these drugs work and t…
Frontiers May 27, 2026
Narrative review of palmitoleic acid links to metabolic health and fatty liver outcomes
Nutrition & Obesity Medicine Sys. Review
Narrative review of palmitoleic acid links to metabolic health and fatty liver outcomes Palmitoleic Acid Shows Mixed Links to Metabolic Health
This narrative review examines palmitoleic acid (POA) supplementation and food matrices regarding insulin resistance, fatty liver, and hyper…
Higher palmitoleic acid levels are tied to fatty liver and insulin resistance, but supplements show neutral effects.
Frontiers May 26, 2026
Olezarsen showed no significant difference versus placebo in noncalcified plaque volume change over 12 months in adults with moderate hypertriglyceridemia
Cardiology RCT
Olezarsen showed no significant difference versus placebo in noncalcified plaque volume change over 12 months in adults with moderate hypertriglyceridemia New trial shows olezarsen did not reduce plaque volume compared to placebo in adults with high triglycerides
This randomized, placebo-controlled trial enrolled 468 adults with moderate hypertriglyceridemia and followed them for 12 months. The primar…
A study of 468 adults found that taking olezarsen did not lower plaque volume better than taking a dummy pill. Safety was also similar betwe…
May 19, 2026
Case report and review of literature on acute NSTEMI after fluorescein angiography in a 76-year-old woman
Ophthalmology Sys. Review
Case report and review of literature on acute NSTEMI after fluorescein angiography in a 76-year-old woman Rare heart attack possible after fluorescein angiography in older adults with heart disease
This case report and review of the literature describes a 76-year-old woman with hypertension, hyperlipidemia, and type 2 diabetes mellitus …
A 76-year-old woman with heart disease had a heart attack shortly after a dye test, highlighting rare risks.
Frontiers May 18, 2026
Narrative review on managing hypertriglyceridemia in pregnancy, including olezarsen and volanesorsen
Diabetes & Endocrinology Sys. Review
Narrative review on managing hypertriglyceridemia in pregnancy, including olezarsen and volanesorsen High Triglycerides In Pregnancy Need New Safe Drug Options Soon
This narrative review synthesizes evidence on hypertriglyceridemia in pregnancy. It covers lifestyle and pharmacologic options, noting trigl…
Pregnant women with very high triglycerides face dangerous risks but safe new drugs are not yet approved for use during delivery.
Frontiers May 8, 2026
FDA Approves Crestor (rosuvastatin) for Cardiovascular Risk Reduction in Adults
Cardiology FDA Approval
FDA Approves Crestor (rosuvastatin) for Cardiovascular Risk Reduction in Adults FDA approves Crestor to prevent heart attacks and strokes in certain adults.
FDA approved Crestor (rosuvastatin) to reduce risk of major adverse cardiovascular events in adults without established coronary heart disea…
The FDA approved Crestor (rosuvastatin) to reduce the risk of heart attack, stroke, and related events in adults without heart disease but w…
FDA May 5, 2026
Pitavastatin lowers LDL and MACE risk in people with HIV on stable antiretroviral therapy
Infectious Disease RCT
Pitavastatin lowers LDL and MACE risk in people with HIV on stable antiretroviral therapy This cholesterol drug cuts heart risk for people with HIV
This secondary analysis of a phase 3 trial examined pitavastatin versus placebo in people with HIV aged 40 to 75 years on stable antiretrovi…
A large trial found that a daily statin cut heart risk by more than a third in people with HIV, even when their cholesterol looked fine.
May 2, 2026
Chiglitazar reduces liver fat in MASLD patients with hypertriglyceridemia and insulin resistance
Gastroenterology RCT
Chiglitazar reduces liver fat in MASLD patients with hypertriglyceridemia and insulin resistance Two doses of chiglitazar cut liver fat far more than a placebo in 18 weeks
In a phase II randomized, double-blind, placebo-controlled trial, 104 patients with MASLD, hypertriglyceridemia, and insulin resistance rece…
Patients with fatty liver disease and high triglycerides saw liver fat drop significantly with chiglitazar compared to placebo after 18 week…
May 1, 2026
Exploratory analysis of RYGB and SG shows variable LDL cholesterol response in patients with obesity and high LDL cholesterol
Nutrition & Obesity Medicine RCT
Exploratory analysis of RYGB and SG shows variable LDL cholesterol response in patients with obesity and high LDL cholesterol Two bariatric surgeries lower cholesterol through completely different biological paths
This exploratory analysis of a randomized clinical trial (BASALTO) evaluated 30 patients with obesity and high LDL cholesterol undergoing Ro…
New research shows that two popular weight loss surgeries lower bad cholesterol in very different ways that could change how doctors pick a …
May 1, 2026
Plozasiran reduces recurrent pancreatitis in familial chylomicronaemia syndrome post hoc analysis
Drug Pipeline RCT
Plozasiran reduces recurrent pancreatitis in familial chylomicronaemia syndrome post hoc analysis New drug slashes pancreatitis attacks in high-risk patients
This post hoc analysis of a Phase 3 RCT in 67 adults with very severe hypertriglyceridemia and pancreatitis history found that subcutaneous …
A new treatment cuts pancreatitis flare-ups in people with dangerously high blood fats, offering hope for those with few options and constan…
May 1, 2026

Questions about Hyperlipidemia

What are the research gaps regarding using Rhaponticum for Hyperlipidemia?

Research on Rhaponticum for hyperlipidemia is limited to preclinical studies; no human trials confirm its lipid-lowering effects, safety, or dosing.

Full answer →
How does Crestor lower cardiovascular risk for adults with elevated cholesterol levels?

Crestor (rosuvastatin) lowers cardiovascular risk by reducing LDL cholesterol and inflammation, as shown in clinical trials and real-world studies.

Full answer →
Is there evidence that quercetin is effective for managing Hyperlipidemia?

Quercetin shows promise for hyperlipidemia in lab and animal studies, but human clinical evidence is still lacking. It is not a proven treatment.

Full answer →
Will Rhaponticum species help treat my condition known as Hyperlipidemia?

Rhaponticum species show hypolipidemic effects in animal and lab studies, but human clinical trials are lacking, so it is not a proven treatment for hyperlipidemia.

Full answer →

All Hyperlipidemia Articles